Compare ARTNA & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARTNA | VSTM |
|---|---|---|
| Founded | 1905 | 2010 |
| Country | United States | United States |
| Employees | 274 | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 356.0M | 395.4M |
| IPO Year | N/A | 2011 |
| Metric | ARTNA | VSTM |
|---|---|---|
| Price | $34.16 | $5.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 30.3K | ★ 3.2M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.99% | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,914,000.00 |
| Revenue This Year | $7.82 | $282.64 |
| Revenue Next Year | $3.54 | $72.25 |
| P/E Ratio | $15.23 | ★ N/A |
| Revenue Growth | N/A | ★ 209.14 |
| 52 Week Low | $30.50 | $3.43 |
| 52 Week High | $34.90 | $11.25 |
| Indicator | ARTNA | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 57.19 | 75.12 |
| Support Level | $31.87 | $5.53 |
| Resistance Level | $34.86 | $6.10 |
| Average True Range (ATR) | 0.74 | 0.43 |
| MACD | -0.04 | 0.17 |
| Stochastic Oscillator | 44.37 | 97.19 |
Artesian Resources Corp operates as a holding company based in the United States. Through its subsidiaries, it offers water, wastewater, and other services in Delaware, Maryland, and Pennsylvania. The Group distributes and sells water, including water for public and private fire protection, to residential, commercial, industrial, municipal, and utility customers. Additionally, it is involved in contract water and wastewater operations; offers wastewater services, and water, sewer, and internal Service Line Protection Plans. The Group operates its businesses mainly through one reportable segment, the Regulated Utility segment.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.